Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What are the indications for tagrisso in nsclc?

See the DrugPatentWatch profile for tagrisso

What FDA Approvals Cover Tagrisso for NSCLC?


Tagrisso (osimertinib) is approved for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with exon 19 deletions or exon 21 L858R mutations in EGFR, detected by an FDA-approved test.[1]

It is also approved for adjuvant therapy after tumor resection in patients with NSCLC harboring the same EGFR mutations (exon 19 deletions or exon 21 L858R), with no evidence of stage IV disease.[1]

Additional approval exists for treatment of locally advanced or metastatic NSCLC with EGFR T790M mutation, detected by an FDA-approved test, in patients whose disease progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.[1]

How Do Patients Get Tested for These Mutations?


EGFR mutation status is confirmed via tumor biopsy or plasma (liquid biopsy). FDA-approved companion diagnostics include cobas EGFR Mutation Test v2 and therascreen EGFR Plasma RGQ PCR Kit. Testing occurs before starting Tagrisso to match the specific mutation.[1]

What Stages of NSCLC Does Tagrisso Target?


Primarily metastatic (stage IV) or locally advanced NSCLC, and early-stage (IB-IIIA) as adjuvant post-surgery. It does not have approvals for frontline use in EGFR wild-type NSCLC or other mutation subtypes like exon 20 insertions without prior TKI failure.[1]

When Was Tagrisso First Approved for NSCLC and What Expanded It?


Initial FDA approval came in 2015 for T790M-mutated metastatic NSCLC post-EGFR TKI progression. Expanded in 2018 to first-line metastatic EGFR-mutated NSCLC based on FLAURA trial data showing improved progression-free and overall survival. Adjuvant approval followed in 2020 from ADAURA trial.[1][2]

How Does Tagrisso Compare to Other EGFR TKIs in NSCLC?


Tagrisso, a third-generation irreversible EGFR TKI, outperforms first-generation (erlotinib, gefitinib) and second-generation (afatinib, dacomitinib) TKIs in first-line settings per FLAURA trial: median progression-free survival of 18.9 months vs. 10.2 months for first-gen TKIs.[2] It crosses the blood-brain barrier better, addressing CNS metastases common in EGFR-mutated NSCLC.[1]

What Limitations or Exclusions Apply?


Not indicated for NSCLC without EGFR mutations. Use requires confirmed mutation status. No approval as monotherapy in frontline for non-EGFR mutated disease or combination frontline without specific trial data.[1]

[1]: FDA Label for Tagrisso
[2]: NEJM: FLAURA Trial



Other Questions About Tagrisso :

Tagrisso astrazeneca price? How much is tagrisso? Tagrisso cost? Tagrisso potencia? Tagrisso specialty pharmacy network? Resistance tagrisso? What are the side effects of tagrisso?

AI-Drug Label Prescribing Information Alignment Report

62
62%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Most core on-label indications and key FLAURA efficacy figures are supported by the provided label sections; however, several claims are unsupported or overgeneralized (e.g., companion diagnostic therascreen kit, blood-brain barrier, drug classification/irreversibility, approval-year/timeline claims, and “common” CNS metastases).


Category Scores

Indication
78
Good

Accurate Statements

Tagrisso is approved for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations detected by an FDA-approved test.
Indications and Usage (1.3)
Testing occurs before starting Tagrisso to match the specific mutation.
Patient Selection (2.2) and Recommended Evaluation and Testing Before Initiating TAGRISSO (2.1)
Tagrisso is not indicated for NSCLC without EGFR mutations (as shown in the provided indications requiring specific EGFR mutations detected by an FDA-approved test).
Indications and Usage (1.1, 1.3, 1.5) and Patient Selection (2.2)
Use of Tagrisso requires confirmed mutation status.
Patient Selection (2.2)
Tagrisso has no frontline approval in EGFR wild-type NSCLC (frontline indication in provided sections is restricted to exon 19 deletions or exon 21 L858R).
Indications and Usage (1.3)
In first-line settings in FLAURA, median PFS is 18.9 months vs 10.2 months for gefitinib/erlotinib comparators.
Clinical Studies (14.3), Table 16
In FLAURA first-line settings, Tagrisso shows improved progression-free and overall survival compared with first-generation TKIs (gefitinib/erlotinib).
Clinical Studies (14.3)
Tagrisso has no approval as monotherapy in frontline for non-EGFR mutated disease (frontline monotherapy indication provided is restricted to specified EGFR exon 19 deletion/L858R mutations).
Indications and Usage (1.3) and Patient Selection (2.2)
Tagrisso does not have frontline approval for mutation subtypes other than exon 19 deletions or exon 21 L858R (e.g., exon 20 insertions not shown as an approved frontline indication in provided sections).
Indications and Usage (1.3) and Patient Selection (2.2)

Unsupported Statements

FDA-approved companion diagnostics for EGFR mutations include cobas EGFR Mutation Test v2 and therascreen EGFR Plasma RGQ PCR Kit.
The provided label sections mention cobas EGFR Mutation Test and cobas EGFR Mutation Test v2, but do not mention therascreen EGFR Plasma RGQ PCR Kit.
Tagrisso crosses the blood-brain barrier better.
No provided label section contains blood-brain barrier language.
Tagrisso is a third-generation irreversible EGFR TKI.
No provided label sections describe generation or irreversibility.
Initial FDA approval for Tagrisso in NSCLC was in 2015 for T790M-mutated metastatic NSCLC after EGFR TKI progression.
The provided label sections do not state approval year.
FDA approval for Tagrisso was expanded in 2018 to first-line metastatic EGFR-mutated NSCLC.
The provided label sections do not state approval expansion year.
FDA approval for Tagrisso adjuvant therapy followed in 2020 from the ADAURA trial.
The provided label sections do not state approval year.
Tagrisso has no approval for combination frontline therapy without specific trial data.
Provided sections describe combination use (FLAURA2) but do not include an explicit labeling statement about limitations tied to 'without specific trial data.'

Contradictions


Important Omissions

Administration/dosage instructions for Tagrisso (e.g., dosing amount, frequency, duration) were not evaluated because the AI claims provided mainly address indications/selection and certain efficacy results, not dosing.
Importance: Low

Safety Assessment

Potential Patient Risk: Moderate
Unsupported claims about diagnostics (companion kit name), drug classification mechanism, blood-brain barrier, and approval timeline are not directly dosing/safety instructions, but they can mislead label-concordant use and expectations.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Multiple claims are not supported by the provided label text (e.g., therascreen companion diagnostic, blood-brain barrier, third-generation/irreversible classification, and approval-year/timeline assertions).

Suggested Improvement
Restrict claims to the provided label-supported language (indications, required EGFR mutations detected by an FDA-approved test, and the documented study efficacy numbers). Remove or rephrase unsupported diagnostic kit names, mechanistic descriptors not present in the label excerpts, and approval timeline statements.

Drug Brand Mention Assessment

Branding Score
68
Visibility
76
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
mentioned only
Brand Perception
Best Known For

outperforms first-generation (erlotinib, gefitinib) and second-generation (afatinib, dacomitinib) TKIs in first-line settings


Core Claims
  • Approved for first-line metastatic NSCLC with exon 19 deletions or exon 21 L858R EGFR mutations
  • Approved for adjuvant therapy after tumor resection in NSCLC with the same EGFR mutations and no stage IV disease
  • Approved for locally advanced or metastatic NSCLC with EGFR T790M after progression on/after EGFR TKI therapy
  • Requires confirmed EGFR mutation status using biopsy or plasma testing and FDA-approved companion diagnostics
Differentiators
  • Described as a third-generation irreversible EGFR TKI
  • Said to outperforms first- and second-generation TKIs in first-line settings per FLAURA trial
  • Said to cross the blood-brain barrier better to address CNS metastases

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Eli Lilly and Company 0%
0 # No
AstraZeneca 0%
0 # No